China's BeiGene, Merck KGaA Expand Cancer-Drug Partnership
This article was originally published in PharmAsia News
BeiGene and Merck KGaA have signed an agreement to develop the China biotech's BeiGene-290 cancer drug, expanding a partnership that began earlier this year with two other BeiGene cancer treatments.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.